At a glance
ClinicalIndex Comparison Record- ✓Age 60-85 years
- ✓English as first or primary language
- ✓Adequate sensorimotor function and verbal expressive abilities
- ✓Has weekly in-person contact co-participant willing to participate as collateral informant
- ✕TICS score ≤19 suggestive of dementia
- ✕Prior diagnosis of Dementia (NIA-AA) or Major Neurocognitive Disorder (DSM-5)
- ✕Daily/weekly anticholinergic or sedative use
- ✕History of significant/unstable conditions affecting cognition: cardiac disease, infection, metabolic disease, cancer, developmental disorder, neurologic disease
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Transcranial Magnetic Stimulation for MCI: A Phase II Dose-Response Study
In Brief
A clinical study evaluating Accelerated iTBS and Sham Comparator for Mild Cognitive Impairment and Depression. Currently recruiting, targeting 60 participants across 1 site.
Detailed Summary
The goal of this phase II study is to establish the dose-response curves of a safe and clinically feasible non-invasive brain stimulation technique (accelerated Transcranial Magnetic Stimulation (TMS)) to improve both depression and cognitive function in Mild Cognitive Impairment (MCI) patients with comorbid depression. It is known that TMS can effectively treat depression. Identifying the right dose of accelerated TMS in MCI patients is necessary prior to designing subsequent trials to determine efficacy. These results will inform future clinical trials of accelerated TMS for MCI, with the long-term goal of developing an efficacious treatment to prevent dementia.
Study Details
Timeline
Interventions
The investigators will treat participants with accelerated intermittent theta burst stimulation. iTBS will be delivered via a MagVenture MagPro TMS System with a Cool-B65 coil, targeting to direct the stimulation to the left dorsolateral prefrontal cortex (l-dlPFC). The investigators will use a standard resting motor threshold (rMT) determination to determine the TMS dose. Treatment will be delivered at 120% of the motor threshold. Total treatment time will be controlled; all participants will perceive receiving active treatment for 10 3-min sessions with 10-15 min inter-session intervals, resulting in a 3-hour treatment day. At pre-treatment, a focal electrical sham will be individually titrated to participant tolerability. Participants then receive an individualized level of sham stimulation throughout treatment, to bolster the blind. Participants will be told that they will be receiving different doses throughout the treatment day, again to maintain the integrity of the blind.
To achieve adequate blinding, participants will go through the same number of sessions per day irrespective of the active and/or sham dose-step combination to which they are assigned. Sham sessions will be assigned in random order over the 10 sessions. The sequence of active and/or sham sessions for each treatment day is assigned a random code that is entered into the TMS system by the coordinator to maintain the integrity of the blind.